Application No.: 10/646267 Docket No.: CCI-007USDV

### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

# **Listing of Claims:**

1. (Currently Amended) A method of inhibiting the activity of a G1 cdk, the method including comprising contacting said cdk with a substance that includes a peptide of 40 amino acids or less, the peptide including comprising the motif:

## **KxxRRyFzP**

#### wherein

- (a) x comprises any amino acid;
- (b) y and z comprise hydrophobic amino acids;
- (c) K is present, deleted or replaced by another amino acid; and
- (d) P is present, deleted or replaced by another amino acid.

-<u>KxxRRyFzP</u> (wherein x may be any amino acid, y and z may be hydrophobic, and each of the underlined residues may be absent or different).

- 2. (Currently Amended) [[A]] The method according to claim 1 wherein at least one of y or z comprises an amino acid selected from the group consisting of y or / and z is, or are independently, any one of: alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan[[,]] and methionine.
- 3. (Currently Amended) [[A]]The method according to claim 1, wherein said peptide is a fragment of p21 or an active portion or derivative thereof.
- 4. (Currently Amended) [[A]]The method according to claim 1, wherein said peptide consists of residues 16-35 of the p21<sup>WAF1</sup> amino acid sequence or an active portion or derivative thereof.

Application No.: 10/646267 Docket No.: CCI-007USDV

5. (Currently Amended) [[A]]The method according to claim 3 or elaim 4, wherein said peptide is a said active portion or a said derivative and said active portion or said derivative has at least 80% identity with p21 over a window of at least 5 amino acids of p21.

- 6. (Currently Amended) [[A]]The method according to claim 1 wherein said peptide is coupled to a carrier molecule.
- 7. (Currently Amended) [[A]]The method according to claim 6, wherein the carrier molecule has the sequence RQIKIWFQNRRMKWKK.
- 8. (Currently Amended) [[A]]The method according to claim 1 wherein the peptide binds to a G1 cyclin or a G1 cdk.

## 9-10. (Cancelled)

- 11. (Currently Amended) [[A]]<u>The</u> method according to claim 1 or claim 10 wherein the cdk activity includes comprises Rb phosphorylation.
- 12. (Currently Amended) [[A]]<u>The</u> method according to claim 1 or claim 10 wherein induction of cell cycle arrest is tested.